Overview: Breast Cancer and the Pill

1, 2, 3, 4  »

References

1. Kirschstein RL et al. Infiltrating duct carcinoma of the mammary gland of a Rhesus monkey after administration of an oral contraceptive: a preliminary report. JNCI. 1972; 48: 551-553.

2. Geil et al FDA studies of estrogen, progestogens, and estrogen/ progesterone combinations in the dog and monkey. J Tox. Env. Health. 3: 1979.

3. Shubik P. Oral contraceptives and breast cancer: laboratory evidence. In: Interpretation of Negative Epidemiological Evidence for Carcinogenicity. IARC Sci. Publ. 1985: 65; 33.

4. Kahn RH et al. Effect of long-term treatment with norethynodrel on A/J and C3H/Hej mice. Endocrinology 1969; 84: 661.

5. Weisburger JH et al. Reduction in Carcinogen Induced Breast Cancer in rats by an anti-fertility drug. Life Sci. 1968; 7: 259.

6. Welsch CW et al. 17B-Estradiol and enovid mammary tumorogenesis in C3H/HeJ female mice: counteraction by concurrent 2-bromo-ergo cryptine. Br. J. Cancer. 1977; 35: 322

7. Anderson T, Battersby S, et al. Oral contraceptive use influences resting breast proliferation. Hum. Pathol. 1989; 20: 1139-1144.

9. Brind J, Chinchilli M, Severs W, Summer-Long J. Induced abortion as an independent risk factor for breast cancer: a comprehensive review and meta-analysis. J. Epi. and Comm. Health. 10/ 1996; 50: 481-496.

10. Stewart DR, Overstreet JW et al. Enhanced ovarian steroid secretion before implantation in early human pregnancy. J. of Endo. and Met. 1993; 76: 1470-1476.

11. Norman RJ et al. Inhibin and relaxin concentration in early singleton, multiple, and failing pregnancy: relationship to gonadotropin and steroid profiles. Fertility and Sterility. 1993; 59: 130-137.

12. Pike MC, Henderson BE et al. Oral contraceptive use and early abortion as risk factors for breast cancer in young women. British Journal of Cancer. 1981; 43: 72-76.

13. Wingo PA, Lee NC et al. Age-specific differences in the relationship between oral contraceptives use and breast cancer. Cancer (supplement). 1993; 71: 1506-17

14. Chilvers C, McPherson K, et al. Oral contraceptive use and breast cancer risk in young women {UK National Case-Control Study Group}. The Lancet. May 6, 1989: 973-982.

15. Brinton LA, Daling JR et al. Oral contraceptives and breast cancer risk among younger women. JNCI. 6/7/1995; 87: 827-35.

16. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53,297 women with breast cancer and 100,239 women without breast cancer from 54 epidemiological studies. The Lancet 1996; 347: 1713-1727.

17. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormonal contraceptives: further results. Contraception. 1996; 34: S1-S106.

18. Rosenberg L, Palmer JR, et al. Case-control study of oral contraceptive use and risk of breast cancer. American Journal of Epidemiology. 1996; 143: 25-37.

19. White E, Malone K, Weiss N, Daling J. Breast cancer among young US women in relation to oral contraceptive use. JNCI. 1994; 86: 505-514.

20. Thomas DB. Oral contraceptives and breast cancer: review of the epidemiological literature. Contraception. 1991; 43: 597-642

21. Romieu I, Berlin J, et al. Oral contraceptives and breast cancer. Cancer. 1990; 66: 2253-2263

22. Hankinson SE, et al. A prospective study of oral contraceptive use and risk of breast cancer (Nurses Health Study, United States). Cancer Causes and Control. 1997; 8: 65-72.

23. Beral V, et al. Mortality associated with oral contraceptive use: 25 year follow up of cohort of 46,000 women from Royal College of General Practitioners' oral contraception study. Br. Med J. 318. 1/1999: 96-99.

24. Rookus MA, Leeuwen FE. Oral contraceptives and risk of breast cancer in women ages 20-54 years. Lancet. 1994; 344: 844-851.

25. Weinstein A, Mahoney M, et al. Breast cancer risk and oral contraceptive use: results from a large case-control study. Epidemiology. 1991; 2: 353-358.

26. Palmer J, Rosenberg L, et al. Oral contraceptives use and breast cancer risk among African-American women. Cancer Causes and Control. 1995; 6: 321-331.

27. Thomas DB, Noonan EA. Breast cancer and combined oral contraceptives: results from a multinational study [The WHO collaborative study of Neoplasia and steroid contraceptives]. Br. J of Cancer. 1990; 61: 110-119.

28. Wang Q, Ross R, et al. A case-control study of breast cancer in Tianjin, China. Cancer Epidemiology. 1992; 1: 435-439.

29. Miller D, Rosenberg L, et al. Breast cancer before age 45 and oral contraceptive use: new findings. American Journal of Epidemiology. 1989; 129: 269-279.

30. Colton T, Greenberg ER, et al. Breast cancer in mothers prescribed diethylstilbestrol in pregnancy. JAMA, 1993; 269: 2096-3000.

31. Thomas DB et al. Oral contraceptives and invasive adenocarcinomas and adenosquamos carcinomas of the uterine cervix. American J. of Epidemiology. 1996; 144: 281-289.

32. Ebeling K. et al. Use of oral contraceptives and risk of invasive cervical cancer in previously screened women. Int J. of Cancer. 1987; 39: 427-430.

33. Kenya PR. Oral contraceptive use and liver tumours: a review. East African Medical Journal. 1990. 67:146-153.

34. Thomas DB, et al. Invasive squamos-cell cervical carcinoma and combined oral contraceptives: Results from a multinational study. Int J Cancer. 1993; 53: 228-236.

35. Parkin et al. Estimates of the worldwide frequency of sixteen major cancers in1980. Int. J of Cancer. 1988. 41: 184-197.

36. Fauci AS et al. Harrison's: Principle of Internal Medicine 14th edition. McGraw Hill Inc. NY.(C) 1998.

37. Earl DT, et al. Calcium channel blockers and dysmenorrhea. Journal of Adolescent Medicine. 1992; 13: 107-108.

38. Skegg DCG, Noonan EA, et al. Depot medroxyprogesterone acetate and breast cancer [A pooled analysis of the World Health Organization and New Zealand studies]. 1995; JAMA: 799-804.

39. Clubb EM et al. A pilot study on teaching NFP in general practice: current knowledge and new strategies for the 1990s. Washington, DC Georgetown University, 1990: 130-132.

40. Frank-Hermann P et al Effectiveness and acceptability of the symptothermal method of NFP in Germany. Am. J. of Obstet. Gyn. 1991; 165: 2052-45.

41. Liezola MA. De premiere d'une etude prospecive d'efficacite du planning famillial naturel realisee en Belgique francophone. J. Gyncol. Obstet. Biol. Rev. 1994, 23: 359-364.

42. Dorairaj K. The modification mucus method in India. Am. J. Ob. Gyn. 1991; 165: 2066-67.

43. Ryder RE. "Natural Family Planning": Effective birth control supported by the Catholic Church. BMJ. 1993; 307: 723-6.

For more information on NFP call or write to:

1, 2, 3, 4  »